Startup · $11.7m raised
Every investor coverage indicates participated in a round Recce Pharmaceuticals raised.
| Investor | Rounds | Invested |
|---|---|---|
| Endpoints Capital | Grant | $11,178,965 |
| NorthStar Impact Funds | Unnamed stage | - |
Companies Recce Pharmaceuticals acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Recce Pharmaceuticals. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Wholesale Investor's Steve Torso highlights Australian life sciences companies from the Emergence Preview Series, noting government grant funding, a Series A extension, venture co-investment, and a medtech company's ASX listing.
Also Wholesale Investor
Manufacturing roundup: OncoSil Medical locks in commitments for an $8.7 million raise, Soilco completes its purchase of Martins Fertilizers, Avecho collects an R&D rebate, alongside items on apprenticeships, Myriota, Recce and Swinburne research.
Also thecfigroup.com·divestmergeacquire.com·redchip.com.au·wastemanagementreview.com.au
Profile of Australian biotech Recce Pharmaceuticals, whose synthetic antibiotic candidates target drug-resistant infections, covering its leadership team, FDA designation, clinical trial progress and a government underwriting of its R&D rebate.
Roundup: Orthocell reports higher revenue, Recce Pharmaceuticals raises $8 million via a placement, executive appointments at Blacktree and Memphasys, Crosbe launches low-carbon grouts, NSW forms a Net Zero Commission, QUT unveils mapping research.
Fremantle Seaweed, Vanable, FLK it over, Bae Juice, Nullify, Recce Pharmaceuticals, Broad Radio, VaultEscrow, Esper, Anni, CSF Enterprises, and Jupiter Ionics secured funding through various rounds including crowdfunding, seed, and grants.
Also SmartCompany·SmartCompany
Recce Pharmaceuticals secures an $11.2m advance from Endpoints Capital against its research rebate, plus a record $54.9m federal overseas finding, easing pressure on its drug-development spending.
Also Early VC
InvestorHub, formerly Fresh Equities, raised $4 million led by EVP to grow revenue and expand overseas, helping listed companies engage shareholders.
Radium Capital's explainer on R&D financing describes how ventures including Juice Batteries, Recce Pharmaceuticals, SSW Dairy, Linecrest, NeedleCalm and iCommand used Radium Advances against their R&D tax refunds as non-dilutive debt capital.
Manufacturing roundup: 3D Metalforge raises funds via placement, Recce Pharmaceuticals lands an R&D tax rebate, CoDeAc unveils a nuclear detection solution, A2EP plans a webinar, and Varley Rafael advances local missile production.
Techboard's annual report finds Australian early-stage startup funding passed $10 billion in FY21, up 64%, while WA companies attracted just $50 million, with ASX raises dominating and female founders' funding share falling.
Drug developer Recce Pharmaceuticals has secured nearly $28 million through a share placement to speed commercialisation and pay for human clinical trials of its anti-infective candidates.
Manufacturing briefs covering SciDev's US equipment order, Reece Pharmaceuticals' antibiotic trial results, and Wheatbelt companies sharing Western Australian government regional development grants, including Bruce Rock Engineering.